Monte Rosa Therapeutics (GLUE) to Release Earnings on Thursday

Monte Rosa Therapeutics (NASDAQ:GLUE) is projected to issue its quarterly earnings data before the market opens on Thursday, March 13th. Analysts expect the company to announce earnings of ($0.27) per share for the quarter.

Monte Rosa Therapeutics Stock Performance

NASDAQ:GLUE opened at $6.11 on Wednesday. The stock has a 50-day simple moving average of $6.18 and a 200 day simple moving average of $6.77. Monte Rosa Therapeutics has a 52-week low of $3.21 and a 52-week high of $12.40. The company has a market cap of $375.38 million, a PE ratio of -3.34 and a beta of 1.50.

Wall Street Analyst Weigh In

Separately, Wells Fargo & Company cut shares of Monte Rosa Therapeutics from an “overweight” rating to an “equal weight” rating and decreased their price target for the stock from $14.00 to $11.00 in a research note on Thursday, December 19th.

Monte Rosa Therapeutics Company Profile

Monte Rosa Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops MRT-2359, an orally bioavailable molecular glue degrader targeting the translation termination factor protein GSPT1 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of systemic and central nervous system autoimmune diseases; and MRT-8102 for the treatment of IL-1?/NLRP3 driven inflammatory diseases.